Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Evonik

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    AR101

    ACTIVE PHARMA INGREDIENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 10,359Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA panelists largely endorse Aimmune's peanut allergy therapy
    FDA panelists largely endorse Aimmune's peanut allergy therapy

    14 Sep 2019

    // Natalie Grover ENDPTS

    https://endpts.com/its-not-perfect-but-its-a-good-start-fda-panelists-largely-endorse-aimmunes-peanut-allergy-therapy/

    Natalie Grover ENDPTS
    14 Sep 2019
    Share Share
    FDA Allergenic Products Advisory Committee Votes to Aimmune’s PALFORZIA™
    FDA Allergenic Products Advisory Committee Votes to Aimmune’s PALFORZIA™

    13 Sep 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190913005515/en

    BUSINESSWIRE
    13 Sep 2019
    Share Share
    Aimmune to Present AR101 Data at European Academy of Allergy
    Aimmune to Present AR101 Data at European Academy of Allergy

    24 May 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190524005106/en/Aimmune-Present-AR101-Data-European-Academy-Allergy/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    BUSINESSWIRE
    24 May 2019
    Share Share
    Phase III results move Aimmune’s peanut allergy drug closer to EU market
    Phase III results move Aimmune’s peanut allergy drug closer to EU market

    27 Mar 2019

    // Anna Smith PHARMA TIMES

    http://www.pharmatimes.com/news/phase_iii_results_move_aimmunes_peanut_allergy_drug_closer_to_eu_market_1282738

    Anna Smith PHARMA TIMES
    27 Mar 2019
    Share Share
    Aimmune drug application confusion leaves investors searching for answers
    Aimmune drug application confusion leaves investors searching for answers

    19 Jan 2019

    // Ned Pagliarulo BIOPHARMA DIVE

    https://www.biopharmadive.com/news/aimmune-drug-application-confusion-leaves-investors-searching-for-answers/546348/

    Ned Pagliarulo BIOPHARMA DIVE
    19 Jan 2019
    Share Share
    Aimmune Therapeutics Submits BLA to FDA for AR101
    Aimmune Therapeutics Submits BLA to FDA for AR101

    21 Dec 2018

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20181221005567/en

    BUSINESSWIRE
    21 Dec 2018
    Share Share